Peptidream Inc.

Bristol-myers Squibb Compnay

The University of Tokyo

Tokyo Metropolitan Institute of Medical Science

Daiichi Sankyo Company, Limited

Patrick Reid

Paul Michael Scola

Kap-Sun Yeung

Takashi Kawakami

David R Langley

Li-Qiang Sun

Eric P Gillis

Hiroshi Murakami

Kenneth M Boy

Eric Mull

Michael Matthew Miller

Michael S Bowsher

Martin Patrick Allen

Toru Sasaki

Claudio Mapelli

Michinori Kohara

Juliang Zhu

Maude A Poirier

Keiichi Masuya

Masaki Ohuchi

Daniel J Tenney

Nishith Sanghvi

Kiichi Kubota

Takahiro Yamaguchi

Hiroaki Suga

Hideki Kubota

Akihiro Furukawa

Yutaka Mori

Hironao Saito

Eri Otsuka

Kenji Kashiwagi

Hiroshi Ijiri

Takahiro Ishizawa

Yutaka Ishigai

Provided are linkers suitable for preparing a conjugate of a nucleic acid and a peptide as a translation product thereof in a reconstituted cell-free translation system in genotype-phenotype mapping (display methods), said linkers comprising a single-stranded structure region having a side chain base pairing with the base at the 3′-end of an mRNA at one end and a peptidyl acceptor region containing an amino acid attached to an oligo RNA consisting of a nucleotide sequence of ACCA via an ester bond at the other end, characterized in that the ester bond is formed by using an artificial RNA catalyst. Also provided are display methods using [mRNA]-[linker]-[peptide] conjugates assembled via such linkers.

Rapid display method in translational synthesis of peptide

Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia. Specifically provided is a macrocyclic polypeptide represented by formula (I) [wherein A is selected from the linking groups Ato A; Xis a residue of an aliphatic amino acid, an aromatic amino acid, a basic amino acid, a neutral amino acid, or an acidic amino acid, or is absent; Xis a residue of an aromatic amino acid or a neutral amino acid; Xis a residue of an aliphatic amino acid, an aromatic amino acid, or a basic amino acid; Xis Ser, Thr, Ala, orS; Xis Gly or Ser; Xis a residue of a basic amino acid or a neutral amino acid; Xis a residue of a neutral amino acid or an acidic amino acid; Xis a residue of an aromatic amino acid; Xis a residue of an aliphatic amino acid, a neutral amino acid, or an aromatic amino acid; Xis a residue of a basic amino acid, an aliphatic amino acid, an aromatic amino acid, or a neutral amino acid; Xis a residue of an aromatic amino acid; and Xis a residue of an aliphatic amino acid, an aromatic amino acid, or a basic amino acid], or a pharmacologically acceptable salt thereof.

Thrombospondin 1-binding peptide

An object of the present invention is to provide a method of producing a peptide containing a charged non-proteinogenic amino acid in a cell-free translation system, and the like. The present invention provides a method of producing a peptide containing a charged non-proteinogenic amino acid. It includes a step of expressing a peptide in a cell-free translation system including (i) at least one tRNA to which a non-proteinogenic amino acid having a protecting-group-introduced charged group has been bound and (ii) a nucleic acid that encodes the peptide and contains at least one codon corresponding to an anticodon of the tRNA; and a step of removing the protecting group of the non-proteinogenic amino acid residue contained in the peptide.

Production method for charged non-protein amino acid-containing peptide

An object of the present invention is to provide a method for producing a peptide library capable of incorporating an arbitrary number of arbitrary proteinogenic and/or non-proteinogenic amino acids in an arbitrary site. The invention provides a method for producing a peptide library including 1&#xd7;10or more kinds of peptides containing amino acids encoded by NNN, including a step of preparing an mRNA library including mRNAs which encode peptides of the peptide library and each contain at least one NNN; and a step of translating each mRNA of the mRNA library in a cell-free translation system added with tRNA containing an anticodon to any one of NNNcodons and charged with an amino acid corresponding to the codon (wherein, N, N, and Nare each independently selected from adenine (A), guanine (G), cytosine (C), and uracil (U) and an arbitrary amino acid is reassigned to each NNN).

Method for producing peptide library, peptide library, and screening method

Disclosed is a hemagglutinin-binding peptide producing an anti-influenza virus effect higher than that of existing peptides. Also disclosed are hemagglutinin-binding peptides comprising a polypeptide having any of the following amino acid sequences (i) to (iv):

Hemagglutinin-binding peptide

Object of the present invention is to provide a hemagglutinin-binding peptide producing an anti-influenza virus effect higher than that of existing peptides. The present invention provides, for example, a hemagglutinin-binding peptide comprising a polypeptide having any of the following amino acid sequences (i) to (iv):

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions

An object of the present invention is to provide a VEGFR2 inhibitor peptide having high specificity and available at a low cost. The present invention provides a peptide having the following amino acid sequence: [wherein, Xaarepresents Val or derivative thereof, Xaarepresents Asp or derivative thereof, Xaarepresents Pro or derivative thereof, Xaarepresents Trp or derivative thereof, Xaarepresents Asn or derivative thereof, Xaarepresents Gly or derivative thereof, Xaarepresents Leu or derivative thereof, Xaa, Xaato Xaa, Xaa, and Xaato Xaaeach independently represent an arbitrary amino acid or derivative thereof]; or [wherein, Xaarepresents His or derivative thereof, Xaarepresents Pro or derivative thereof, and Xaato Xaaand Xaato Xaaeach represent an arbitrary amino acid].

Peptide for inhibiting vascular endothelial growth factor receptor

Growing community of inventors

Tokyo, Japan

Patrick Reid